C4 Therapeutics, Inc. Payments to Acquire Marketable Securities
C4 Therapeutics, Inc. (CCCC) reported Payments to Acquire Marketable Securities of $111.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- C4 Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $70.83M, a 226.70% increase year-over-year.
- C4 Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $40.81M, a 59.17% increase year-over-year.
- C4 Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $133.07M, a 226.28% increase year-over-year.
- C4 Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $46.68M, a 31.91% decline year-over-year.
- C4 Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $227.07M, a 20.13% decline from fiscal 2024.
- C4 Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $284.32M, a 118.88% increase from fiscal 2023.
- C4 Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $129.90M, a 40.83% decline from fiscal 2022.
- C4 Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $219.53M, a 59.18% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $70.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $111.64M 10-Q · filed 2026-08-11 | $244.71M derived: sum of 3 quarters · filed 2026-08-11 | $291.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $40.81M 10-Q · filed 2026-05-12 | $173.88M derived: sum of 2 quarters · filed 2026-05-12 | $220.57M derived: sum of 3 quarters · filed 2026-05-12 | $242.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $133.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $179.75M derived: sum of 2 quarters · filed 2026-02-26 | $201.43M derived: sum of 3 quarters · filed 2026-08-11 | $227.07M 10-K · filed 2026-02-26 |
| 2025-09-30 | $46.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $68.36M derived: sum of 2 quarters · filed 2026-08-11 | $94.00M 10-Q · filed 2025-11-06 | $134.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $21.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $47.32M 10-Q · filed 2026-08-11 | $88.10M derived: sum of 3 quarters · filed 2026-08-11 | $156.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $25.64M 10-Q · filed 2026-05-12 | $66.42M derived: sum of 2 quarters · filed 2026-05-12 | $134.99M derived: sum of 3 quarters · filed 2026-05-12 | $202.21M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $40.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $109.35M derived: sum of 2 quarters · filed 2026-02-26 | $176.57M derived: sum of 3 quarters · filed 2026-02-26 | $284.32M 10-K · filed 2026-02-26 |
| 2024-09-30 | $68.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $135.79M derived: sum of 2 quarters · filed 2025-11-06 | $243.54M 10-Q · filed 2025-11-06 | $281.42M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $67.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $174.97M 10-Q · filed 2025-08-07 | $212.85M derived: sum of 3 quarters · filed 2025-08-07 | $244.79M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $107.75M 10-Q · filed 2025-05-07 | $145.63M derived: sum of 2 quarters · filed 2025-05-07 | $177.57M derived: sum of 3 quarters · filed 2025-05-07 | $226.21M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $37.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $69.82M derived: sum of 2 quarters · filed 2025-02-27 | $118.46M derived: sum of 3 quarters · filed 2025-02-27 | $129.90M 10-K · filed 2025-02-27 |
| 2023-09-30 | $31.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $80.58M derived: sum of 2 quarters · filed 2024-10-31 | $92.02M 10-Q · filed 2024-10-31 | $148.31M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $48.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $60.08M 10-Q · filed 2024-08-01 | $116.37M derived: sum of 3 quarters · filed 2024-08-01 | $171.47M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $11.44M 10-Q · filed 2024-05-08 | $67.73M derived: sum of 2 quarters · filed 2024-05-08 | $122.83M derived: sum of 3 quarters · filed 2024-05-08 | $154.75M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $56.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $111.39M derived: sum of 2 quarters · filed 2024-02-22 | $143.31M derived: sum of 3 quarters · filed 2024-02-22 | $219.53M 10-K · filed 2024-02-22 |
| 2022-09-30 | $55.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $87.02M derived: sum of 2 quarters · filed 2023-11-01 | $163.24M 10-Q · filed 2023-11-01 | $308.65M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $31.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $108.13M 10-Q · filed 2023-08-08 | $253.55M derived: sum of 3 quarters · filed 2023-08-08 | $408.25M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $76.22M 10-Q · filed 2023-05-04 | $221.63M derived: sum of 2 quarters · filed 2023-05-04 | $376.34M derived: sum of 3 quarters · filed 2023-05-04 | $437.66M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $145.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $300.12M derived: sum of 2 quarters · filed 2023-02-23 | $361.44M derived: sum of 3 quarters · filed 2023-02-23 | $537.74M 10-K · filed 2023-02-23 |
| 2021-09-30 | $154.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $216.02M derived: sum of 2 quarters · filed 2022-11-03 | $392.32M 10-Q · filed 2022-11-03 | $550.20M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $61.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $237.62M 10-Q · filed 2022-08-04 | $395.50M derived: sum of 3 quarters · filed 2022-08-04 | $427.54M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $176.30M 10-Q · filed 2022-05-05 | $334.18M derived: sum of 2 quarters · filed 2022-05-05 | $366.22M derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $157.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $189.91M derived: sum of 2 quarters · filed 2022-02-24 | $293.86M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $32.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $135.98M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $103.94M 10-Q · filed 2021-08-11 | |||
| 2019-12-31 | $79.00M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |